Background/Aims: Hypertension is one of the most significant prognostic factors of immunoglobulin A nephropathy (IgAN). We investigated the role of polymorphisms of hypertension-related genes in the clinical impact of IgAN. Methods: A total of 238 IgAN and 300 healthy cohorts were studied. The polymorphisms of angiotensinogen (AGT M235T), the angiotensin II type 1 receptor (A1166C), aldosterone synthase (C-344T), α-adducin (G460W) and endothelin-1 (K198N and 3A/4A) were determined. Results: The genotype distributions of the polymorphisms were similar between patients and controls. The individual genotypes taken alone were not associated with the development of hypertension or progression of renal dysfunction. Although AGT M235T was not associated with the development of hypertension in either sex, men with M235T TT were found to be at an increased risk of IgAN progression compared to those with the other genotypes (p = 0.019). In the Cox regression model with adjustment for clinical risk factors, including age at diagnosis, hypertension, serum creatinine and urinary protein excretion at renal biopsy, AGT M235T TT variant was an independent risk factor only for male patients (hazard ratio 5.848; p = 0.005). Conclusion: Our results suggest that the AGT M235T polymorphism is associated with the progression of IgAN in Korean male patients.

Keywords:
IgA nephropathy, Hypertension, Genetic polymorphism, Angiotensinogen, Gender
1.
D’Amico G: Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. Semin Nephrol 2004;24:179–196.
2.
Deenitchina SS, Shinozaki M, Hirano T, Ando T, Hirakata H, Kiyohara Y, Katafuchi R, Fujishima M: Association of a T-cell receptor constant alpha chain gene polymorphism with progression of IgA nephropathy in Japanese patients. Am J Kidney Dis 1999;34:279–288.
3.
Shu KH, Lee SH, Cheng CH, Wu MJ, Lian JD: Impact of interleukin-1 receptor antagonist and tumor necrosis factor-alpha gene polymorphism on IgA nephropathy. Kidney Int 2000;58:783–789.
4.
Pei Y, Scholey J, Thai K, Suzuki M, Cattran D: Association of angiotensinogen gene T235 variant with progression of immunoglobin A nephropathy in Caucasian patients. J Clin Invest 1997;100:814–820.
5.
Song J, Narita I, Goto S, Saito N, Omori K, Sato F, Ajiro J, Saga D, Kondo D, Sakatsume M, Gejyo F: Gender specific association of aldosterone synthase gene polymorphism with renal survival in patients with IgA nephropathy. J Med Genet 2003;40:372–376.
6.
Jeunemaitre X, Charru A, Chatellier G, Dumont C, Sassano P, Soubrier F, Menard J, Corvol P: M235T variant of the human angiotensinogen gene in unselected hypertensive patients. J Hypertens 1993;11:S80–S81.
7.
Frimat L, Philippe C, Maghakian MN, Jonveaux P, Hurault de Ligny B, Guillemin F, Kessler M: Polymorphism of angiotensin converting enzyme, angiotensinogen, and angiotensin II type 1 receptor genes and end-stage renal failure in IgA nephropathy: IGARAS – a study of 274 men. J Am Soc Nephrol 2000;11:2062–2067.
8.
Bonnardeaux A, Davies E, Jeunemaitre X, Fery I, Charru A, Clauser E, Tiret L, Cambien F, Corvol P, Soubrier F: Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension. Hypertension 1994;24:63–69.
9.
Bantis C, Ivens K, Kreusser W, Koch M, Klein-Vehne N, Grabensee B, Heering P: Influence of genetic polymorphisms of the renin-angiotensin system on IgA nephropathy. Am J Nephrol 2004;24:258–267.
10.
Delles C, Erdmann J, Jacobi J, Hilgers KF, Fleck E, Regitz-Zagrosek V, Schmieder RE: Aldosterone synthase (CYP11B2) -344 C/T polymorphism is associated with left ventricular structure in human arterial hypertension. J Am Coll Cardiol 2001;37:878–884.
11.
Hautanen A, Toivanen P, Manttari M, Ten-kanen L, Kupari M, Manninen V, Kayes KM, Rosenfeld S, White PC: Joint effects of an aldosterone synthase (CYP11B2) gene polymorphism and classic risk factors on risk of myocardial infarction. Circulation 1999;100:2213–2218.
12.
Lovati E, Richard A, Frey BM, Frey FJ, Ferrari P: Genetic polymorphisms of the renin-angiotensin-aldosterone system in end-stage renal disease. Kidney Int 2001;60:46–54.
13.
Cusi D, Barlassina C, Azzani T, Casari G, Citterio L, Devoto M, Glorioso N, Lanzani C, Manunta P, Righetti M, Rivera R, Stella P, Troffa C, Zagato L, Bianchi G: Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension. Lancet 1997;349:1353–1357.
14.
Narita I, Goto S, Saito N, Song J, Ajiro J, Sato F, Saga D, Kondo D, Akazawa K, Sakatsume M, Gejyo F: Interaction between ACE and ADD1 gene polymorphisms in the progression of IgA nephropathy in Japanese patients. Hypertension 2003;42:304–309.
15.
Maixnerova D, Merta M, Reiterova J, Stekrova J, Rysava R, Obeidova H, Viklicky O, Potmesil P, Tesar V: The influence of three endothelin-1 polymorphisms on the progression of IgA nephropathy. Folia Biol (Praha) 2007;53:27–32.
16.
Lee HS, Lee MS, Lee SM, Lee SY, Lee ES, Lee EY, Park SY, Han JS, Kim S, Lee JS: Histological grading of IgA nephropathy predicting renal outcome: revisiting H. S. Lee’s glomerular grading system. Nephrol Dial Transplant 2005;20:342–348.
17.
Lifton RP: Genetic determinants of human hypertension. Proc Natl Acad Sci USA 1995;92:8545–8551.
18.
Maruyama K, Yoshida M, Nishio H, Shirakawa T, Kawamura T, Tanaka R, Nakamura H, Iijima K, Yoshikawa N: Polymorphisms of renin-angiotensin system genes in childhood IgA nephropathy. Pediatr Nephrol 2001;16:350–355.
19.
Alamartine E, Sabatier JC, Guerin C, Berliet JM, Berthoux F: Prognostic factors in mesangial IgA glomerulonephritis: an extensive study with univariate and multivariate analyses. Am J Kidney Dis 1991;18:12–19.
20.
Woo KT, Lau YK, Choong LH, Zhao Y, Tan HB, Fook-Chong S, Tan EK, Yap HK, Wong KS: Polymorphism of renin-angiotensin system genes in IgA nephropathy. Nephrology (Carlton) 2004;9:304–309.
21.
Hunley TE, Julian BA, Phillips JA, 3rd, Summar ML, Yoshida H, Horn RG, Brown NJ, Fogo A, Ichikawa I, Kon V: Angiotensin converting enzyme gene polymorphism: Potential silencer motif and impact on progression in IgA nephropathy. Kidney Int 1996;49:571–577.
22.
Goto S, Narita I, Saito N, Watanabe Y, Yamazaki H, Sakatsume M, Shimada H, Nishi S, Ueno M, Akazawa K, Arakawa M, Gejyo F: A(-20)C polymorphism of the angiotensinogen gene and progression of IgA nephropathy. Kidney Int 2002;62:980–985.
23.
D’Amico G, Minetti L, Ponticelli C, Fellin G, Ferrario F, Barbiano di Belgioioso G, Imbasciati E, Ragni A, Bertoli S, Fogazzi G, et al: Prognostic indicators in idiopathic IgA mesangial nephropathy. Q J Med 1986;59:363–378.
24.
Silbiger SR, Neugarten J: The impact of gender on the progression of chronic renal disease. Am J Kidney Dis 1995;25:515–533.
25.
Neugarten J, Acharya A, Silbiger SR: Effect of gender on the progression of nondiabetic renal disease: a meta-analysis. J Am Soc Nephrol 2000;11:319–329.
26.
Cattran DC, Reich HN, Beanlands HJ, Mil-ler JA, Scholey JW, Troyanov S: The impact of sex in primary glomerulonephritis. Nephrol Dial Transplant 2008;23:2247–2253.
27.
Shen P, He L, Li Y, Wang Y, Chan M: Natural history and prognostic factors of IgA nephropathy presented with isolated microscopic hematuria in Chinese patients. Nephron Clin Pract 2007;106:c157–c161.
28.
Freire MB, Ji L, Onuma T, Orban T, Warram JH, Krolewski AS: Gender-specific association of M235T polymorphism in angiotensinogen gene and diabetic nephropathy in NIDDM. Hypertension 1998;31:896–899.
29.
Rogus JJ, Moczulski D, Freire MB, Yang Y, Warram JH, Krolewski AS: Diabetic nephropathy is associated with AGT polymorphism T235: results of a family-based study. Hypertension 1998;31:627–631.
30.
Tien KJ, Hsiao JY, Hsu SC, Liang HT, Lin SR, Chen HC, Hsieh MC: Gender-dependent effect of ACE I/D and AGT M235T polymorphisms on the progression of urinary albumin excretion in Taiwanese with type 2 diabetes. Am J Nephrol 2008;29:299–308.
31.
Miller JA, Anacta LA, Cattran DC: Impact of gender on the renal response to angiotensin II. Kidney Int 1999;55:278–285.
32.
Reckelhoff JF, Hennington BS, Moore AG, Blanchard EJ, Cameron J: Gender differences in the renal nitric oxide (NO) system: dissociation between expression of endothelial NO synthase and renal hemodynamic response to NO synthase inhibition. Am J Hypertens 1998;11:97–104.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.